These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 20510104

  • 21. Mycophenolate mofetil as a treatment for refractory idiopathic thrombocytopenic purpura.
    Zhang WG, Ji L, Cao XM, Chen YX, He AL, Liu J, Zhao WH, Zou SP.
    Acta Pharmacol Sin; 2005 May; 26(5):598-602. PubMed ID: 15842780
    [Abstract] [Full Text] [Related]

  • 22. Successful treatment with the monoclonal antibody rituximab in two children with refractory autoimmune thrombocytopenia.
    Pusiol A, Cesaro S, Nocerino A, Picco G, Zanesco L, Bisogno G.
    Eur J Pediatr; 2004 Jun; 163(6):305-7. PubMed ID: 15346911
    [Abstract] [Full Text] [Related]

  • 23. Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura.
    Zhou Z, Yang R.
    Crit Rev Oncol Hematol; 2008 Jan; 65(1):21-31. PubMed ID: 17681784
    [Abstract] [Full Text] [Related]

  • 24. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis.
    Garcia-Chavez J, Majluf-Cruz A, Montiel-Cervantes L, Esparza MG, Vela-Ojeda J, Mexican Hematology Study Group.
    Ann Hematol; 2007 Dec; 86(12):871-7. PubMed ID: 17874322
    [Abstract] [Full Text] [Related]

  • 25. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.
    Koulova L, Alexandrescu D, Dutcher JP, O'Boyle KP, Eapen S, Wiernik PH.
    Am J Hematol; 2005 Jan; 78(1):49-54. PubMed ID: 15609292
    [Abstract] [Full Text] [Related]

  • 26. Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag.
    Chouhan JD, Herrington JD.
    Pharmacotherapy; 2010 Jul; 30(7):666-83. PubMed ID: 20575632
    [Abstract] [Full Text] [Related]

  • 27. Therapeutic effects of rituximab combined with cyclophosphamide on refractory idiopathic thrombocytopenic purpura.
    Wang J, Wang B, Sun Z, Xue K.
    Exp Ther Med; 2019 Mar; 17(3):2137-2142. PubMed ID: 30867701
    [Abstract] [Full Text] [Related]

  • 28. Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results.
    Medeot M, Zaja F, Vianelli N, Battista M, Baccarani M, Patriarca F, Soldano F, Isola M, De Luca S, Fanin R.
    Eur J Haematol; 2008 Sep; 81(3):165-9. PubMed ID: 18510702
    [Abstract] [Full Text] [Related]

  • 29. [Persistent hypogammaglobulinemia in an ITP patient following treatment with rituximab].
    Toubi E.
    Harefuah; 2012 Nov; 151(11):620-1, 655. PubMed ID: 23367731
    [Abstract] [Full Text] [Related]

  • 30. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab.
    Stasi R, Cooper N, Del Poeta G, Stipa E, Laura Evangelista M, Abruzzese E, Amadori S.
    Blood; 2008 Aug 15; 112(4):1147-50. PubMed ID: 18375792
    [Abstract] [Full Text] [Related]

  • 31. [Levels of regulatory T cells in peripheral blood of children with idiopathic thrombocytopenic purpura].
    Wang XP, Qiu YS, Hao GP, Zhu L.
    Zhongguo Dang Dai Er Ke Za Zhi; 2011 Apr 15; 13(4):282-4. PubMed ID: 21507294
    [Abstract] [Full Text] [Related]

  • 32. [Rituximab treatment of chronic idiopathic thrombocytopenic purpura. Results of a phase II study].
    Meo P, Stipa E, La Presa M, Bianchi M, Di Giulio C, Stasi R, Amadori S.
    Recenti Prog Med; 2002 Apr 15; 93(7-8):421-7. PubMed ID: 12138687
    [Abstract] [Full Text] [Related]

  • 33. [Clinical analysis of lower doses rituximab for children primary immune thrombocytopenia].
    Liu X, Huang Y, Chen Y, Liu W, Xue F, Zhang L, Yang R.
    Zhonghua Xue Ye Xue Za Zhi; 2014 Dec 15; 35(12):1079-82. PubMed ID: 25543701
    [Abstract] [Full Text] [Related]

  • 34. Successful use of rituximab in refractory idiopathic thrombocytopenic purpura in a patient with common variable immunodeficiency.
    Al-Ahmad M, Al-Rasheed M, Al-Muhani A.
    J Investig Allergol Clin Immunol; 2010 Dec 15; 20(3):259-62. PubMed ID: 20635793
    [Abstract] [Full Text] [Related]

  • 35. [Use of rituximab in resistant thrombocytopenic purpura].
    Zambrano-Velarde MA, de la O-Peña D, Chávez-Peña Q, Bedolla-Barajas M.
    Rev Med Inst Mex Seguro Soc; 2012 Dec 15; 50(2):203-8. PubMed ID: 22882991
    [Abstract] [Full Text] [Related]

  • 36. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura.
    Zaja F, Battista ML, Pirrotta MT, Palmieri S, Montagna M, Vianelli N, Marin L, Cavallin M, Bocchia M, Defina M, Ippoliti M, Ferrara F, Patriarca F, Avanzini MA, Regazzi M, Baccarani M, Isola M, Soldano F, Fanin R.
    Haematologica; 2008 Jun 15; 93(6):930-3. PubMed ID: 18403395
    [Abstract] [Full Text] [Related]

  • 37. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
    Zaja F, Iacona I, Masolini P, Russo D, Sperotto A, Prosdocimo S, Patriarca F, de Vita S, Regazzi M, Baccarani M, Fanin R.
    Haematologica; 2002 Feb 15; 87(2):189-95. PubMed ID: 11836170
    [Abstract] [Full Text] [Related]

  • 38. B-cell compartment as the selective target for the treatment of immune thrombocytopenias.
    Zaja F, Vianelli N, Sperotto A, De Vita S, Iacona I, Zaccaria A, Masolini P, Tomadini V, Tani M, Molinari AL, Baccarani M, Fanin R.
    Haematologica; 2003 May 15; 88(5):538-46. PubMed ID: 12745273
    [Abstract] [Full Text] [Related]

  • 39. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura.
    Bennett CM, Rogers ZR, Kinnamon DD, Bussel JB, Mahoney DH, Abshire TC, Sawaf H, Moore TB, Loh ML, Glader BE, McCarthy MC, Mueller BU, Olson TA, Lorenzana AN, Mentzer WC, Buchanan GR, Feldman HA, Neufeld EJ.
    Blood; 2006 Apr 01; 107(7):2639-42. PubMed ID: 16352811
    [Abstract] [Full Text] [Related]

  • 40. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura.
    Cooper N, Stasi R, Cunningham-Rundles S, Feuerstein MA, Leonard JP, Amadori S, Bussel JB.
    Br J Haematol; 2004 Apr 01; 125(2):232-9. PubMed ID: 15059147
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.